Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
by ruth on January 25, 2007

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as generalized anxiety disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of mutagenicity, antigenicity or carcinogenicity. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.
MediciNova acquired a license to MN-305 from Mitsubishi Pharma Corporation for global markets, with the exception of Japan and other selected Asian countries.
Source: MediciNova
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/50678
Mr Wong
Vote for MediciNova Initiates Phase II Trial on Insomnia Pill:
|
Rating: 10.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







